X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4) 4
index medicus (4) 4
multiple myeloma (4) 4
hematology, oncology and palliative medicine (3) 3
oncology (3) 3
bone marrow (2) 2
consensus (2) 2
hemic and lymphatic diseases (2) 2
multiparameter flow-cytometry (2) 2
multiple myeloma - drug therapy (2) 2
positron-emission-tomography (2) 2
proteins (2) 2
studies (2) 2
transplants & implants (2) 2
abridged index medicus (1) 1
adult (1) 1
aged (1) 1
analysis (1) 1
anemia (1) 1
antibodies, monoclonal - administration & dosage (1) 1
antibodies, monoclonal - adverse effects (1) 1
antibodies, monoclonal - therapeutic use (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic agents - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
asthma (1) 1
autografts (1) 1
binding sites (1) 1
biological products (1) 1
biomarkers (1) 1
biomarkers, tumor (1) 1
biopsy (1) 1
bone cancer (1) 1
bone marrow cells (1) 1
bone marrow cells - pathology (1) 1
bone-marrow (1) 1
canada (1) 1
care and treatment (1) 1
carfilzomib (1) 1
cd38 antigen (1) 1
circulating plasma-cells (1) 1
cytotoxicity (1) 1
daratumumab (1) 1
diagnosis (1) 1
disease management (1) 1
disease-free survival (1) 1
drug administration schedule (1) 1
drug dosages (1) 1
drug resistance, neoplasm (1) 1
drug screening (1) 1
drug therapy (1) 1
drugs (1) 1
early intervention (1) 1
early treatment strategies (1) 1
elotuzumab (1) 1
extramedullary disease (1) 1
fda approval (1) 1
fees & charges (1) 1
female (1) 1
flow cytometry (1) 1
fluorodeoxyglucose f18 (1) 1
free light-chain (1) 1
hematology (1) 1
hematology [human health sciences] (1) 1
high-dose chemotherapy (1) 1
hématologie [sciences de la santé humaine] (1) 1
imaging techniques (1) 1
immunoglobulins (1) 1
immunomodulation (1) 1
immunosuppressive agents (1) 1
independent risk-factor (1) 1
inhibitors (1) 1
interactive systems (1) 1
internal medicine (1) 1
intravenous administration (1) 1
islam (1) 1
islamic modernism (1) 1
kaplan-meier estimate (1) 1
lenalidomide plus dexamethasone (1) 1
librarians (1) 1
libraries (1) 1
light-chain ratio (1) 1
lymphomas (1) 1
male (1) 1
marrow plasma-cells (1) 1
medical colleges (1) 1
medical prognosis (1) 1
medicine (1) 1
medicine, general & internal (1) 1
methods (1) 1
middle aged (1) 1
monoclonal antibodies (1) 1
monoclonal gammopathy (1) 1
multicenter (1) 1
multiple myeloma - diagnosis (1) 1
multiple myeloma - pathology (1) 1
multiple myeloma, minimal residual disease (1) 1
neoplasm recurrence, local - drug therapy (1) 1
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10027, pp. 1551 - 1560
Summary Background New treatment options are needed for patients with multiple myeloma that is refractory to proteasome inhibitors and immunomodulatory drugs.... 
Internal Medicine | SURVIVAL | MEDICINE, GENERAL & INTERNAL | RISK | MULTICENTER | THERAPY | ELOTUZUMAB | Drug Administration Schedule | United States | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Kaplan-Meier Estimate | Neoplasm Recurrence, Local - drug therapy | Antibodies, Monoclonal - therapeutic use | Drug Resistance, Neoplasm | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Spain | Canada | Disease-Free Survival | Multiple Myeloma - drug therapy | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adult | Female | Aged | Drugs | Medical colleges | Biological products | Multiple myeloma | Monoclonal antibodies | Product development | Lymphomas | Drug therapy | Care and treatment | Analysis | Studies | Protease inhibitors | Hematology | Stem cells | Cytotoxicity | Patients | Drug dosages | Slopes | Therapy | Schedules | Intravenous administration | Stem cell transplantation | Transplantation | Drug screening | Immunosuppressive agents | Randomization | CD38 antigen | Autografts | Anemia | Immunomodulation | Research & development--R&D | FDA approval | Survival | Proteasome inhibitors | Asthma | Refractory materials | Inhibitors | Interactive systems | Response rates
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 8, pp. e328 - e346
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 12, pp. e538 - e548
Journal Article
The Lancet Oncology, ISSN 1470-2045, 04/2017, Volume 18, Issue 4, pp. e206 - e217
The International Myeloma Working Group consensus aimed to provide recommendations for the optimal use of fluorodeoxyglucose ( F-FDG) PET/CT in patients with... 
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.